High Contrast PET Imaging of Subcortical and Allocortical Amyloid-β in Early Alzheimer's Disease Using [11C]AZD2184

J Alzheimers Dis. 2024;98(4):1391-1401. doi: 10.3233/JAD-231013.

Abstract

Background: Deposits of amyloid-β (Aβ) appear early in Alzheimer's disease (AD).

Objective: The aim of the present study was to compare the presence of cortical and subcortical Aβ in early AD using positron emission tomography (PET).

Methods: Eight cognitively unimpaired (CU) subjects, 8 with mild cognitive impairment (MCI) and 8 with mild AD were examined with PET and [11C]AZD2184. A data driven cut-point for Aβ positivity was defined by Gaussian mixture model of isocortex binding potential (BPND) values.

Results: Sixteen subjects (3 CU, 5 MCI and 8 AD) were Aβ-positive. BPND was lower in subcortical and allocortical regions compared to isocortex. Fifteen of the 16 Aβ-positive subjects displayed Aβ binding in striatum, 14 in thalamus and 10 in allocortical regions.

Conclusions: Aβ deposits appear to be widespread in early AD. It cannot be excluded that deposits appear simultaneously throughout the whole brain which has implications for improved diagnostics and disease monitoring.

Keywords: Alzheimer’s disease; amygdala; amyloid deposits; entorhinal cortex; hippocampus; positron emission tomography; striatum; thalamus.

MeSH terms

  • Alzheimer Disease* / metabolism
  • Aminopyridines*
  • Amyloid beta-Peptides / metabolism
  • Benzothiazoles*
  • Carbon Radioisotopes
  • Cognitive Dysfunction* / diagnostic imaging
  • Cognitive Dysfunction* / metabolism
  • Humans
  • Neocortex* / metabolism
  • Positron-Emission Tomography / methods

Substances

  • 2-(6-(methylamino)pyridin-3-yl)-1,3-benzothiazol-6-ol
  • Carbon-11
  • Carbon Radioisotopes
  • Amyloid beta-Peptides
  • Aminopyridines
  • Benzothiazoles